Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.
about
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosisCytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation studyA Guide to Non-Alcoholic Fatty Liver Disease in Childhood and AdolescenceLiver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.Liver biopsy in modern clinical practice: a pediatric point-of-viewNoninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients.Non-invasive diagnosis of advanced fibrosis and cirrhosis.Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.Invasive and non-invasive diagnosis of cirrhosis and portal hypertensionMultiparametric magnetic resonance for the non-invasive diagnosis of liver disease.Can NASH be diagnosed, graded, and staged noninvasively?Fatty liver disease in children: eat now pay later.Nonalcoholic fatty liver disease as a comorbidity of childhood obesity.Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challengeUse of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control studyReview article: the management of paediatric nonalcoholic fatty liver disease.Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.The human hyaluronan synthase 2 (HAS2) gene and its natural antisense RNA exhibit coordinated expression in the renal proximal tubular epithelial cellTissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 productionThe performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.Noninvasive diagnosis of pediatric nonalcoholic fatty liver diseaseEnhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV.The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C CoinfectionNon-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.Advances in pediatric nonalcoholic fatty liver disease.Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.Nonalcoholic fatty liver disease: a challenge for pediatricians.Non-invasive assessment of liver fibrosis: it is time for laboratory medicine.Transient elastography for assessment of fibrosis in paediatric liver disease.Mechanisms and biomarkers of apoptosis in liver disease and fibrosis.Molecular serum markers of liver fibrosis.Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?Noninvasive evaluation of NAFLD.
P2860
Q21261905-3BB3FDE9-213F-4B8F-A383-7B3B396DC432Q24657221-4217C98D-55C2-4744-93FB-692EA9A595CEQ26744488-57AFD882-06F9-418A-9B77-C940D975CDECQ26780252-67017B43-D8E6-4942-8B37-7DF871DD59E4Q26826920-C8E57627-6B15-4BFC-89F1-A3079B05E71BQ28082686-46CB9D7E-9298-4042-9CA7-1BCAC8B24FF5Q28084035-50A4A554-626A-4989-ABED-75BBEE104144Q30398914-7EF923DB-D7AB-4BCF-9D0D-7F7C2F368C0AQ30423320-9393147B-6FAE-4685-9BD3-16BF946A4BAEQ30432576-ABB01784-4E38-459D-93F5-8546FB853FC2Q30439743-2E62D88B-4C6F-4319-AEAB-9D338E7F8F9FQ30445138-37CF1284-2C6F-4ABB-99A0-0523312DBCD5Q30451362-7DC114A7-92D2-4255-96A7-2AF3AC5C92C4Q33718945-2047786B-BAE6-4EBA-9669-856B0D36EF02Q33913788-FA1A5FD0-C294-4D9F-B753-D767768852EEQ34390296-6369F641-1B36-4E46-823E-9F3BCC1954C1Q34414807-75A82E15-1497-4C29-9E84-84942B362D5EQ34440962-0FC6A480-6A30-4868-98FD-D245B0D66434Q34532528-CB1EF7B4-594F-43A1-8C10-3BF5825C6BB8Q34981143-9FB1D60A-30CF-40E3-A43D-0243A0502448Q35010973-598C10B0-8BE3-4CA8-972B-F13115A92000Q35073951-88072147-A861-4979-8D45-15B745C6F5F2Q35149314-25CA3A4A-1C08-4EAA-9698-B3672BDD6638Q35405041-7E22A016-F62D-4F6D-BDD8-B1543E3ED6ACQ35872069-646C8938-ADD5-40D8-8C4B-A2BD74B8265DQ36654566-15EB8047-D193-4026-9EAA-D98E9BA279C7Q36660316-56455B57-9FA5-4E07-BF8B-FF537894CD4DQ36715064-545E678D-B524-448A-B7D7-624EFD55E0F0Q36788997-4F54AEFB-BC63-4247-8C16-264C319E86B3Q37014002-25E3DC86-3C82-4083-863B-9DD56BED0484Q37192623-7FDBC93D-FD1E-46DB-A906-7B20BE43AA6EQ37376332-77DAECFA-8918-4B6D-BFD9-715836ED56BFQ37417603-12C4C6CB-7393-4984-9449-2FCF78DABCEEQ37788538-B9352164-F858-48D1-83FE-C66C82F4BCABQ37801658-6955A6BD-8626-4660-80DA-9B769652707DQ37890296-19E7FCE3-A4F6-4A46-A695-70D00BC839F5Q38008400-72CE3C49-7062-489C-ADFE-6DCE093B9C8FQ38032835-47197B75-7F93-48CD-835A-B38CDDAB91C9Q38066240-2E96C21D-52D3-4F74-AFA7-D492E54D58BAQ38141711-FED365FF-D4AF-4FC8-A061-182A0E9B4E63
P2860
Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Performance of ELF serum marke ...... alcoholic fatty liver disease.
@en
Performance of ELF serum marke ...... alcoholic fatty liver disease.
@nl
type
label
Performance of ELF serum marke ...... alcoholic fatty liver disease.
@en
Performance of ELF serum marke ...... alcoholic fatty liver disease.
@nl
prefLabel
Performance of ELF serum marke ...... alcoholic fatty liver disease.
@en
Performance of ELF serum marke ...... alcoholic fatty liver disease.
@nl
P2093
P50
P1433
P1476
Performance of ELF serum marke ...... -alcoholic fatty liver disease
@en
P2093
Gianfranco Bottazzo
Julie Parkes
Massimo Pinzani
Matilde Marcellini
Richard Cross
P304
P356
10.1053/J.GASTRO.2008.09.013
P407
P577
2008-09-20T00:00:00Z